Investigational Drug Details
| Drug ID: | D103 |
| Drug Name: | Deferasirox |
| Synonyms: | Deferasirox |
| Type: | Chemical drug |
| DrugBank ID: | DB01609 |
| DrugBank Description: | Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions. |
| PubChem ID: | 214348 |
| CasNo: | 201530-41-8 |
| Repositioning for NAFLD: | Yes |
| SMILES: | Oc1c(c2n(nc(n2)c2c(O)cccc2)c2ccc(cc2)C(=O)O)cccc1 |
| Structure: |
|
| InChiKey: | BOFQWVMAQOTZIW-UHFFFAOYSA-N |
| Molecular Weight: | 373.368 |
| DrugBank Targets: | Iron chelator |
| DrugBank MoA: | Two molecules of deferasirox are capable of binding to 1 atom of iron. Deferasirox works in treating iron toxicity by binding trivalent (ferric) iron (for which it has a strong affinity), forming a stable complex which is eliminated via the kidneys. |
| DrugBank Pharmacology: | Deferasirox is an orally active chelator that is selective for iron (as Fe3+). It is a tridentate ligand that binds iron with high affinity in a 2:1 ratio. Although deferasirox has very low affinity for zinc and copper there are variable decreases in the serum concentration of these trace metals after the administration of deferasirox. The clinical significance of these decreases is uncertain. |
| DrugBank Indication: | For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older. |
| Targets: | -- |
| Therapeutic Category: | Chelating agent |
| Clinical Trial Progress: | Phase 1&2 completed (NCT01278056) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0247 | NCT01278056 | Phase 1/Phase 2 | Completed | No Results Available | March 2010 | July 20, 2012 | Details |
| L0680 | EUCTR2009-012916-41-DE | Not applicable | Not Recruiting | No Results Available | 24/07/2009 | 24 July 2012 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A10228 | 31421090 | Eur J Pharmacol | Iron chelators in obesity therapy - Old drugs from a new perspective? | Details |
| A25872 | 21372165 | Am J Physiol Gastrointest Liver Physiol | Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats. | Details |
| A46499 | 18245813 | Am J Pathol | Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. | Details |